UK regulator approves J&J’s oral psoriasis pill Icotyde
The UK Medicines and Healthcare products Regulatory Agency gave its approval to Johnson & Johnson’s oral psoriasis treatment, Icotyde. The drug is cleared for patients aged 12 and older who weigh at least 40 kg, based on four clinical trials involving 2,500 participants that showed superiority to placebo. J&J projects the product could generate up to $5 billion in peak sales across its approved indications.
Why it matters
The approval opens a new revenue stream for Johnson & Johnson, with the company forecasting $5 billion in peak sales, which could boost its earnings outlook. The product will compete directly with existing therapies such as Bristol Myers Squibb’s Sotyktu and AbbVie’s Skyrizi.
Key facts
- 1The UK MHRA approved J&J’s oral psoriasis pill Icotyde. timeslive.co.za
- 2Icotyde is approved for patients aged 12 years and older who weigh at least 40 kg. timeslive.co.za
- 3Approval was based on four trials that enrolled a total of 2,500 participants. timeslive.co.za
- 4J&J expects the drug to achieve peak sales of $5 billion across multiple indications. timeslive.co.za
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.